Compare · ABT vs ONC
ABT vs ONC
Side-by-side comparison of Abbott Laboratories (ABT) and BeOne Medicines Ltd. (ONC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ONC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $181.14B, about 4.3x ONC ($42.53B).
- ABT has been more active in the news (13 items in the past 4 weeks vs 3 for ONC).
- ABT has more recent analyst coverage (25 ratings vs 7 for ONC).
- Company
- Abbott Laboratories
- BeOne Medicines Ltd.
- Price
- -
- -
- Market cap
- $181.14B
- $42.53B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 13
- 3
- Recent ratings
- 25
- 7
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- Barclays initiated coverage on Abbott Labs with a new price target
- Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- SEC Form 4 filed by Director Roman Michael F
- Abbott Labs upgraded by Rothschild & Co Redburn with a new price target
- Abbott hosts conference call for third-quarter earnings
Latest ONC
- SEC Form 4 filed by BeOne Medicines Ltd.
- SVP, General Counsel Lee Chan Henry sold $418,125 worth of American Depositary Shares (1,115 units at $375.00) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- Chair, Scientific Advisory Brd Wang Xiaodong exercised 31,028 units of American Depositary Shares at a strike of $36.90 and sold $11,318,558 worth of American Depositary Shares (31,028 units at $364.79) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by BeOne Medicines Ltd.
- Chair, Scientific Advisory Brd Wang Xiaodong sold $13,366,092 worth of American Depositary Shares (38,287 units at $349.10) as part of a pre-agreed trading plan and exercised 31,027 units of American Depositary Shares at a strike of $36.90, closing all direct ownership in the company (SEC Form 4)
- Principal Accounting Officer Ball Titus B. sold $46,974 worth of American Depositary Shares (132 units at $355.86), closing all direct ownership in the company (SEC Form 4) (for withholding tax)
- BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
- BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
- BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
- President and COO Wu Xiaobin sold $106,400 worth of American Depositary Shares (280 units at $380.00) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)